FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546213836> ?p ?o ?g. }

• W2546213836 abstract "Abstract The aim of the multi-centre observational study was to evaluate the efficacy of lenalidomide (len) therapy in patients (pts) with resistant or relapsed MM as well in pts who continued treatment with len due to complications from the earlier lines of the therapy. The study involved 306 pts, 153 women and 153 men, aged 26-89 years (mean 60,5); on the onset of lenalidomide therapy 115 pts (38,8 %, Cohort 1, C1) were diagnosed with resistant MM, 135 pts (44,1%, Cohort 2, C2) had relapse of the disease, and 56 (18,3 %, Cohort 3, C3 ) len was instituted as continuation therapy due to polyneuropathy. In Stage I, II and III according to Durie - Salmon staging system there were 36, 88 and 182 pts respectively; 23 pts developed renal failure. 179 pts had IgG myeloma, 78 – IgA, 31pts were diagnosed with light chain disease, 13 – with non-secretory myeloma, 3- IgM, 2 -IgD and 196 with kappa light chain disease. Prior to len therapy the pts received 1-9 treatment lines (mean:3); 83 pts underwent megachemiotherapy. Average time from diagnosis to start of len treatment was 47 months (1-230). In 284 (92,8%) pts, len was administered at the dose of 25mg p.o , on days 1-21, in the remaining 22 (7,2%) pts (14, 3, 5 pts respectively) at the dose of 15mg, 10mg or 5 mg for 21 days, and dexamethasone (dx) at the dose of 20 mg on days 1-4, 8-11. 28 pts received only len at the dose of 25 mg for 21 days; individual pts were administered len with bortezomib or bendamustin and dexamethasone. The cycles were repeated every 28 days. All the pts were administered aspirin 75mg as the prophylaxis of deep vein thrombosis. Therapeutic response was evaluated on the basis of modified criteria of the European Group for Blood and Marrow Transplantation in all pts. At the time of the assessment 32 (10,45% ) pts have completed 1-2 cycles, 48 (15,7%) 3-4 cycles, the others 6 and more. The response rate was highest in pts continuing treatment, significantly higher than in resistant and relapsed myeloma. The response rate in group 1 and 2 was comparable 68,7% i 85,7%.(tabl ) respectively.ResponseResistant MM n=115 (C1);Relapsed MM n=135 (C2);Treatment continuation n=56 (C3);Total (n=306)CR/sCR10 (8,7 %)13 (9,6 %)15 (26,8 %)38VGPR11 (9,6 %)19 (14,1%)19 (33,9 %)49PR58 (50,4%)70 (51,9 %)16 (28,6 %)144SD29 (25,2 %)21 (15,6 %)3 (5,3 %)53PD7 (6,1 %)12 (8,9 %)3 (5,3 %)22Response:79 (68,7%)102 (85,7%)50 (89,2%)No response:36 (31,3%)33 (27,7%)6 (10,%)PC1:C2 =0,2266PC1:C3=0,0033PC2:C3=0,0321 The percentage of all responses was significantly higher in pts without renal insufficiency compared to those with renal failure (224/283 vs. 11/23) p= 0,0006, and in the group of pts whose serum beta-2-microglobulin was <3.5 mg/L compared to those with beta-2-m > 3.5 mg/L 89/112 vs 45/68 p=0,0316. There were no significant differences in response to len, depending on the number of previous lines of treatment 1 vs.> 1, stage ISS, and underwent or no megachemotherapy. The median TTP was 14.0 months in pts who responded to treatment with len and dx (CR, nCR, VGPR, PR). The TTP in pts with disease stabilization, or disease progression was significantly shorter (p = 0.0000), median 5.0 months. The median TTP was 9.0 months in pts with resistant MM, 8.0 months in pts with relapsed MM, and was significantly shorter (p = 0.00007) compared with median TTP in pts continuing treatment (16.50 months). The median OS was 15.0 months in pts who responded to treatment with len and dx (CR, nCR, VGPR, PR), and it was significantly longer (p = 0.00000) than the median OS in pts with disease stabilization, or disease progression (median 8.0 months). In pts with resistant MM median OS was 10.50 months, in pts with relapsed MM -11.0 months, and were significantly shorter (p = 0.00077) comparing to pts continuing treatment (18.0 months). Summary Lenalidomide with dexamethasone is an orally administrated and effective both in resistant and relapsed patients as well as maintenance therapy. Disclosures: No relevant conflicts of interest to declare." @default.
• W2546213836 created "2016-11-04" @default.
• W2546213836 creator A5004816154 @default.
• W2546213836 creator A5006705594 @default.
• W2546213836 creator A5008139866 @default.
• W2546213836 creator A5014557249 @default.
• W2546213836 creator A5016197132 @default.
• W2546213836 creator A5016199509 @default.
• W2546213836 creator A5016868818 @default.
• W2546213836 creator A5020739959 @default.
• W2546213836 creator A5022628384 @default.
• W2546213836 creator A5033354752 @default.
• W2546213836 creator A5046149757 @default.
• W2546213836 creator A5046942962 @default.
• W2546213836 creator A5061136290 @default.
• W2546213836 creator A5084110989 @default.
• W2546213836 creator A5088174608 @default.
• W2546213836 creator A5088246120 @default.
• W2546213836 date "2013-11-15" @default.
• W2546213836 modified "2023-10-14" @default.
• W2546213836 title "Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group" @default.
• W2546213836 doi "https://doi.org/10.1182/blood.v122.21.3236.3236" @default.
• W2546213836 hasPublicationYear "2013" @default.
• W2546213836 type Work @default.
• W2546213836 sameAs 2546213836 @default.
• W2546213836 citedByCount "0" @default.
• W2546213836 crossrefType "journal-article" @default.
• W2546213836 hasAuthorship W2546213836A5004816154 @default.
• W2546213836 hasAuthorship W2546213836A5006705594 @default.
• W2546213836 hasAuthorship W2546213836A5008139866 @default.
• W2546213836 hasAuthorship W2546213836A5014557249 @default.
• W2546213836 hasAuthorship W2546213836A5016197132 @default.
• W2546213836 hasAuthorship W2546213836A5016199509 @default.
• W2546213836 hasAuthorship W2546213836A5016868818 @default.
• W2546213836 hasAuthorship W2546213836A5020739959 @default.
• W2546213836 hasAuthorship W2546213836A5022628384 @default.
• W2546213836 hasAuthorship W2546213836A5033354752 @default.
• W2546213836 hasAuthorship W2546213836A5046149757 @default.
• W2546213836 hasAuthorship W2546213836A5046942962 @default.
• W2546213836 hasAuthorship W2546213836A5061136290 @default.
• W2546213836 hasAuthorship W2546213836A5084110989 @default.
• W2546213836 hasAuthorship W2546213836A5088174608 @default.
• W2546213836 hasAuthorship W2546213836A5088246120 @default.
• W2546213836 hasConcept C126322002 @default.
• W2546213836 hasConcept C143998085 @default.
• W2546213836 hasConcept C2776063141 @default.
• W2546213836 hasConcept C2776364478 @default.
• W2546213836 hasConcept C2777478702 @default.
• W2546213836 hasConcept C2778524551 @default.
• W2546213836 hasConcept C2779609412 @default.
• W2546213836 hasConcept C2780108899 @default.
• W2546213836 hasConcept C71924100 @default.
• W2546213836 hasConceptScore W2546213836C126322002 @default.
• W2546213836 hasConceptScore W2546213836C143998085 @default.
• W2546213836 hasConceptScore W2546213836C2776063141 @default.
• W2546213836 hasConceptScore W2546213836C2776364478 @default.
• W2546213836 hasConceptScore W2546213836C2777478702 @default.
• W2546213836 hasConceptScore W2546213836C2778524551 @default.
• W2546213836 hasConceptScore W2546213836C2779609412 @default.
• W2546213836 hasConceptScore W2546213836C2780108899 @default.
• W2546213836 hasConceptScore W2546213836C71924100 @default.
• W2546213836 hasLocation W25462138361 @default.
• W2546213836 hasOpenAccess W2546213836 @default.
• W2546213836 hasPrimaryLocation W25462138361 @default.
• W2546213836 hasRelatedWork W2011567397 @default.
• W2546213836 hasRelatedWork W2315057995 @default.
• W2546213836 hasRelatedWork W2515009586 @default.
• W2546213836 hasRelatedWork W2521999181 @default.
• W2546213836 hasRelatedWork W2523232626 @default.
• W2546213836 hasRelatedWork W2530826337 @default.
• W2546213836 hasRelatedWork W2535732439 @default.
• W2546213836 hasRelatedWork W2551702777 @default.
• W2546213836 hasRelatedWork W2555603866 @default.
• W2546213836 hasRelatedWork W2558585013 @default.
• W2546213836 hasRelatedWork W2562778144 @default.
• W2546213836 hasRelatedWork W2568583010 @default.
• W2546213836 hasRelatedWork W2576987133 @default.
• W2546213836 hasRelatedWork W2579270792 @default.
• W2546213836 hasRelatedWork W2579933840 @default.
• W2546213836 hasRelatedWork W2585556030 @default.
• W2546213836 hasRelatedWork W2590029659 @default.
• W2546213836 hasRelatedWork W2590205980 @default.
• W2546213836 hasRelatedWork W2979296342 @default.
• W2546213836 hasRelatedWork W3196876910 @default.
• W2546213836 isParatext "false" @default.
• W2546213836 isRetracted "false" @default.
• W2546213836 magId "2546213836" @default.
• W2546213836 workType "article" @default.